About Neotherix

Neotherix was founded in September 2007 by Dr Mike Raxworthy and spun-out from Smith & Nephew (S&N) to develop and commercialise bioresorbable scaffolds for tissue regeneration and repair.

Our Mission

Neotherix’ mission is to develop innovative devices for the repair of problem wounds (acute, surgical, infected and chronic wounds, periodontal disease, colorectal disease) using electrospun scaffolds – polymer networks that provide a patient’s own cells with 3D architecture to repopulate and regenerate a wound space/injury site – thus utilising the body’s ability to repair itself.

Meet the Neotherix Team

Our Technology

Our technology is based on a considerable body of knowledge originally developed by project teams at the S&N Research Centre in York, UK. This technology, available through licence to Neotherix for a wide range of problem wound applications, is based around the polymer processing technique of electrospinning and is being exploited to produce bioresorbable tissue scaffolds tailored to the particular demands of target clinical indications.

Find out more about the technology

Our Strategy

Neotherix’ strategic focus is on Problem Wounds:

  • Acute wounds that can’t be closed by suturing (or primary intention) – particularly cases where a skin graft may be used and/or granulation tissue formation is to be encouraged (secondary intention healing);
  • Chronic wounds – where the need is for diagnostic information and regenerative intervention to push a wound out of a cycle of non-healing;
  • Infected wounds – topical antibiotics may be ineffective and systemic antibiotics present a higher risk so a non-antibiotic (via photodynamically active fibres) approach is attractive. The risk of antimicrobial resistance (AMR) is also reduced.
  • Tracts and tunnels (fistulas and pilonidal sinuses) where the walls of these wounds are encouraged to heal to close the tract.

Neotherix scaffolds are designed to address these pressing clinical needs.